Exploring interaction between genetically predicted body mass index and serum 25-hydroxyvitamin D levels on the odds for psoriasis in UK Biobank and the HUNT Study: A factorial Mendelian randomisation study

Authors: Marita Jenssen^{1, 2*}, Nikhil Arora^{3,4}, Mari Løset^{3,5}, Bjørn Olav Åsvold^{3,6,7}, Laurent Thomas³, Ole-Jørgen Gangsø Bekkevold³, Xiao-Mei Mai⁸, Yi-Qian Sun^{9,10,11}, Anne-Sofie Furberg^{12,13}, Rolf Jorde¹⁴, Tom Wilsgaard², Kjersti Danielsen^{*1,2}, Ben Michael Brumpton^{*3,6}

*These authors share the last authorship

¹ Department of Dermatology, University Hospital of North Norway, Tromsø, Norway

² Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway

³ HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway

⁴ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom

⁵ Department of Dermatology, Clinic of Orthopedy, Rheumatology and Dermatology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

⁶ HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger, Norway

⁷ Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim, Norway

⁸ Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway

⁹ Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway

¹⁰ Department of Pathology, Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim, Norway

¹¹ Center for Oral Health Services and Research Mid-Norway (TkMidt), Trondheim, Norway

¹² Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway

¹³ Faculty of Health Sciences and Social Care, Molde University College, Molde, Norway

¹⁴ Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway

*Corresponding authors:

Ben Michael Brumpton, e-mail: ben.brumpton@ntnu.no

Marita Jenssen, e-mail: marita.jenssen@unn.no

Abstract

Background: Mendelian randomisation (MR) studies show that higher body mass index (BMI) and lower 25-hydroxyvitamin D (25[OH]D) increase psoriasis risk. The combined effect of these factors has not been explored using factorial MR.

Methods: Using cross-sectional data from UK Biobank (UKB, n=398 404) and the Trøndelag Health Study (HUNT, n=86 648), we calculated polygenic risk scores for BMI and 25(OH)D to estimate odds ratios for psoriasis using 2x2 and continuous factorial MR. We quantified additive interaction by relative excess risk due to interaction (RERI)-estimates. We also performed traditional observational analyses in UKB.

Results: There were 12 207 (3.1%) participants with psoriasis in UKB and 7794 (9.0%) in HUNT. In 2x2 factorial MR, we found no evidence of relative excess risk for psoriasis due to interaction between genetically predicted higher BMI and lower 25(OH)D, neither in UKB (RERI -0.01, 95% confidence interval (CI) -0.08, 0.07) nor in HUNT (RERI -0.04, 95% CI -0.14, 0.06). The same was observed in the continuous factorial MR and observational analyses.

Conclusions: This study did not find evidence of interaction between BMI and 25(OH)D on the risk of psoriasis. Given minor differences in measured BMI and 25(OH)D between groups, small effects may have been undetected.

Introduction

Psoriasis is a chronic, inflammatory skin disease which is associated with multiple comorbidities and has considerable impact on quality of life¹. The prevalence varies between populations and geographical locations, and is estimated to be 2-4% among adults in Western countries². However, life-time prevalence as high as 6.6-11.4% has been reported in Norway^{3,4}. Some data indicate increasing prevalence over the past decades⁴⁻⁶.

The obesity epidemic may partly explain the rising psoriasis prevalence, as studies have consistently demonstrated an association between obesity and increased risk of psoriasis⁷⁻⁹. Previous Mendelian randomisation (MR) studies, including European and Japanese populations, have demonstrated a causal relationship from higher body mass index (BMI) to an increased risk of psoriasis^{10,11}. Where reverse causality was found to be unlikely¹¹.

Vitamin D has several effects of importance to skin physiology; of particular relevance to psoriasis is regulation of the immune system, as well as proliferation and maturation of keratinocytes¹². These physiological effects are utilized when treating psoriasis with topical vitamin D analogues¹. Observational studies has found an association between lower serum 25-hydroxyvitamin D (25[OH]D) and psoriasis¹³. MR studies have additionally demonstrated a causal relationship from lower 25(OH)D to an increased risk of psoriasis^{14,15}. Moreover, no reverse causal link has been observed¹⁶.

Recent observational studies suggest that the association between 25(OH)D and psoriasis may be modified by adiposity (BMI and hip-waist ratio)^{14,17,18}. No previous studies have explored this possible combined effect (i.e. interaction) using MR designs, which are considered more robust to residual confounding and reverse causality than traditional observational approaches¹⁹. In factorial MR, genetic variants are used as instrumental variables to assess interaction between modifiable risk factors^{20,21}. Understanding relative excess (disease) risk due to interaction (RERI) can have implications for targeted interventions and public health strategies²².

In this study, we investigated RERI (hereafter referred to as interaction) between genetically predicted BMI and 25(OH)D on psoriasis using observational data from two independent populationbased cohorts; The UK Biobank (UKB) and the Trøndelag Health Study (HUNT). We also explored interaction between measured 25(OH)D and BMI on the odds of psoriasis using a traditional crosssectional design in UKB.

Materials and methods

UK Biobank

UKB is a prospective cohort study including data from approximately 500 000 adult UK citizens (40-69 years old at recruitment) enrolled between March 2006 and July 2010²³. Participants (5.5% of invitees) completed a touchscreen questionnaire, a formal interview, standardised clinical examinations, and biological sampling. Genotyping was performed, and data linked with health records, including hospital records, death registry, and general practitioner data. The latter was available for 45% of participants when we accessed data in May 2023. Details regarding data collection has been described previously²⁴. UKB data-fieldIDs used in this study are listed in the Online supplementary.

We restricted the UKB sample to include white British and unrelated individuals (kinship coefficient cut-off 0.0884) with complete data on the relevant SNPs and valid psoriasis code (flow-chart in

supplementary Figure S1). In total 398 404 participants (214 178 women and 184 226 men) were included in the analysis.

The HUNT Study

HUNT is a population-based cohort study to which adults (≥ 20 years old at recruitment) in Trøndelag County, Norway are invited to repeated surveys^{25,26}. Data is collected through questionnaires, interviews, standardized clinical examinations, biological sampling, and linkage with health records. The number of participants (attendance proportion) was 77 202 (89.4%) in HUNT1 (1984–1986), 65 228 (69.5%) in HUNT2 (1995–1997), 50 800 (54.1%) in HUNT3 (2006–2008), and 56 042 (54.0%) in HUNT4 (2017–2019)²⁵. Among the participants in HUNT2-4, 88 615 individuals have been genotyped²⁷. We excluded non-European participants, those with invalid psoriasis code or missing information on age (flow-chart in supplementary Figure S2). In total 86 648 participants (45 949 women and 40 699 men) were included in the analysis.

Classification of psoriasis

Participants with reported psoriasis either in medical records (ICD codes and/or codes from primary care) or by self-report were classified as having psoriasis.

In UKB we used Date L40 first reported (psoriasis) which combines information from death records, hospital records, primary care data and self-report. The latter was registered if the participant mentioned psoriasis during the formal interview when asked about doctor diagnosed serious illnesses or disabilities.

In HUNT, ICD-codes (ICD9: 696.0/1, ICD10: L40) were available from hospitals and private specialist practitioners and ICPC-2 codes (S91) from general practitioners. Self-reported psoriasis was defined by answering "yes" to the questionnaire question "Have you had, or do you have psoriasis?". Self-reported psoriasis has acceptable validity in HUNT (positive predictive value 78%; 95% confidence interval [CI] 69–85)²⁸. The source psoriasis diagnosis for the included participants are listed in supplementary table S1 and figure S3.

Genetic instruments

In UKB, participants were genotyped using one of two genotyping arrays; The Applied Biosystems UK BiLEVE Axiom Array or Applied Biosystems UK Biobank Axiom Array. In HUNT, genotyping was performed using one of four Illumina HumanCoreExome arrays; HumanCoreExome12 version 1.0, HumanCoreExome12 version 1.1, UM HUNT Biobank version 1.0 or UM HUNT Biobank v2.0. The quality control and the imputation procedures have been described in detail previously^{27,29,30}.

Polygenic risk scores (PRSs) summarise genetic information from several variants into one single variable, with the advantage of explaining a larger amount of variation in a trait compared to single variants³¹. We calculated PRSs for BMI and 25(OH)D (hereafter called BMI-PRS and vitD-PRS, respectively) for each participant as the sum of trait increasing alleles, weighted by the GWAS-effect size of the respective SNP³¹. For our primary analysis, we used a BMI-PRS combining 941 SNPs³². In sensitivity analysis, we used another BMI-PRS combining 77 SNPs³³. For the vitD-PRS we presented combinations of SNPs used in previous MR studies³⁴⁻³⁶. In our primary analysis the vitD-PRS included 21 SNPs from genes with well-known functions in the vitamin D metabolism (*CYP2R1, DHCD7, CYP24A1* and *GC*)³⁷. In sensitivity analyses, we used vitD-PRSs combining 35 SNPs^{34,35}, and 71 SNPs³⁷, respectively. A more detailed description of our selection of SNPs is found in the Online supplementary. Both BMI-PRSs and the vitD-PRS used in our primary analyses have previously been used in one-sample MR studies with psoriasis as outcome, and found to be robust to pleiotropy^{11,37}.

Other measurements

Age was defined by age at first inclusion.

BMI was calculated as weight in kilograms per height in meters squared. Standing height and weight were measured at the assessment centres. For participants with repeated measurements, the first measurement was used. BMI was dichotomised using WHO's proposed threshold for public health action $(BMI > 27.5 \text{ kg/m}^2)^{38}$.

Serum 25(OH)D was measured in UKB using a certified chemiluminescence immunoassay (DiaSorin LIAISON XL, Italy)³⁹. Non-fasting blood samples collected at the assessment centres were stored at minus 80°C before analysis. Season of blood draw was used for seasonal adjustment (December to February = Winter; March to May = Spring; June to August = Summer; September to November = Autumn). All measurements were converted to autumn-measurement by subtracting the respective season mean and adding the autumn mean (e.g., a summer value of 80 nmol/L was converted to season adjusted value by this formula [80 – summer mean + autumn mean])^{15,37}. In HUNT, 25(OH)D measurements were only available for a limited number of participants⁴⁰, and therefore not included in the analysis.

Statistical analyses

Logistic regression was used to estimate odds ratios (ORs) for psoriasis using individual-level data separately in UKB and HUNT.

We dichotomized the BMI-PRS and vitD-PRS by the respective median value (separately for UKB and HUNT). Values equal to or below the median represented low PRS and values above median represented high PRS. Thereafter, participants were separated in four groups based on the dichotomised BMI-PRS and vitD-PRS categories (Figure 1). We expected those with low BMI-PRS and high vitD-PRS (representing lower BMI and higher 25[OH]D) to have lowest odds for psoriasis and chose this group as reference.

We performed 2x2 factorial MR analyses using the four groups based on the dichotomised BMI-PRS and vitD-PRS as an exposure variable. We also performed continuous factorial MR including BMI-PRS, vitD-PRS (both standardised to have a mean of 0 and standard deviation of 1) and their cross-product as predictors. All models included age, sex, genetic batch and 20 principal components^{27,30} (to account for population stratification). To ease comparison with measured BMI and 25(OH)D, we also present the OR estimates (UKB) scaled to represent 5 kg/m² increase in BMI and 10 nmol/L decrease in 25(OH)D.

In UKB, we also performed cross-sectional analyses using observational data. In the continuous approach, predictors were measured 25[OH]D and BMI, and their cross-product. In the 2x2 approach, the predictor was four groups based on dichotomised 25(OH)D (\geq or <25 nmol/L) and BMI (> or \leq 27.5 kg/m²), using 25(OH)D \geq 25 nmol/L + BMI \leq 27.5 kg/m² as a reference group. Adjusted models included age and sex.

Interaction on an additive scale was assessed by estimating RERI^{41,42}. A RERI estimate of zero supports exact additivity, above zero supports positive interaction, and below zero supports negative interaction.

Univariable linear models were applied to assess the association between the respective PRSs and measured 25(OH)D (UKB) and BMI (UKB and HUNT). We evaluated F-statistics and R² estimates to assess the strength of the genetic instruments. Moreover, we explored the association between the PRSs and possible confounders (BMI, age, sex) to assess the second MR assumption (i.e. the

instrument is not associated with confounders). Additionally, the factorial MR was repeated with multiple PRSs to explore potential pleiotropy.

PLINK 2.0 was used to generate PRSs in UKB⁴³. Generation of PRSs in HUNT, and all statistical analyses were performed in R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria). Estimates are reported with a 95% CI.

Ethics

All participants have provided written informed consent. The National Health Service National Research Ethics Service approved the UK Biobank (reference 11/NW/0382). The Regional Committee for Medical and Health Research Ethics (REK) Central approved the HUNT Study. The present study was conducted using the UKB Resource under application number 40135, and was approved by the REK, Mid-Norway (2015/2003).

Results

General characteristics

The UKB sample included 398 404 individuals (53.8% women) with mean (SD) age 56.9 (7.9) years, BMI 27.4 (4.8) kg/m², and season adjusted 25(OH)D 54.8 (19.7) nmol/L (Table 1). The HUNT sample included 86 648 individuals (53.0% women) with mean (SD) age 46.1 (16.9) years and BMI 26.4 (4.4) kg/m² (Table 1).

The prevalence of psoriasis was 3.1% (n=12 207) in UKB and 9.0% (n=7794) in HUNT (Table 1). Participants with psoriasis had on average higher BMI (in both cohorts) and lower 25(OH)D (UKB only) compared to participants without psoriasis.

Table 2 displays general characteristics across the 2x2 factorial MR groups. Having a genetically predicted higher BMI and lower 25(OH)D combined corresponded to an average 1.61 kg/m² higher BMI and 7.39 nmol/L lower 25(OH)D in UKB, and 1.28 kg/m² higher BMI in HUNT (Figure 2). A 1 SD increase in the BMI-PRS corresponded to a 1.05 and 0.81 kg/m² increase in measured BMI in UKB and HUNT, respectively. A 1 SD decrease in the vitD-PRS corresponded to a 4.22 nmol/L lower measured 25(OH)D in UKB.

Genetic instruments

The BMI-PRS (941 SNPs) explained 4.8% of the variation in BMI in UKB (R^2 =4.8%, F-statistic=20180) and 3.4% of the variation in BMI in HUNT (R^2 =3.4%, F-statistic=3065). It was weakly associated with 25(OH)D, age and sex in the UKB, and with age in HUNT (Supplementary table S2a).

The vitD-PRS (21 SNPs) explained 4.6% of the variation in 25(OH)D in UKB (R^2 =4.6%, F-statistic=17490). It was weakly associated with BMI in the UKB, but not in HUNT (Supplementary table S2b).

Factorial MR analysis

In 2x2 factorial MR analyses there was no evidence of relative excess risk for psoriasis due to interaction, neither in UKB (RERI[95% CI]=-0.01[-0.06, 0.09]) nor in HUNT (RERI[95% CI]=-0.04[-0.14, 0.06]) (Figure 2, supplementary table S3a and S3b).

Similarly, we observed no relative excess risk for psoriasis due to interaction in continuous factorial MR analysis assessing the combined effect of 1 SD increase in BMI-PRS (i.e., genetic risk for higher BMI), 1 SD decrease in vitD-PRS (i.e., genetic risk for lower 25[OH]D), and their cross-product, neither in UKB (RERI[95% CI]=0.00[-0.02, 0.02]), nor in HUNT (RERI[95% CI]=0.00[-0.03, 0.02]) (Figure 2 Supplementary table S4a and S4b).

In sensitivity analysis, no substantial differences in the RERI estimates were apparent across PRScombinations in the 2x2 approach (Supplementary table S3a and S3b). In the continuous approach, RERI estimates were close to identical across PRS-combinations (Supplementary table S4a and S4b).

Traditional observational analysis

In UKB, the combined impact of 10 nmol/L decrease in measured 25(OH)D, 5 kg/m² increase in measured BMI, and their cross-product summed to 22% higher odds for psoriasis (OR[95% CI]=1.22[1.09, 1.37]), supporting exact additivity in the observational association (RERI[95% CI]=0.00[-0.01, 0.03]) (Supplementary table S5a). A similar trend was found when scaling the factorial MR analysis (Figure 2).

Support for exact additivity was also found in 2x2 observational analysis; having both 25(OH)D<25 nmol/L and BMI>27.5 was associated with 59% higher odds for psoriasis (OR[95% CI]=1.59[1.40, 1.80]) compared with having both 25(OH)D>25 nmol/L and BMI<27.5 (RERI[95% CI]=0.05[-0.21, 0.32]) (Supplementary table S5b).

Discussion

Main findings

In this factorial MR study, we found no evidence of relative excess risk for psoriasis due to interaction between genetically predicted higher BMI and lower 25(OH)D, neither in UKB nor in HUNT. Moreover, there was no evidence of relative excess risk for psoriasis due to interaction between measured BMI and 25(OH)D in the observational data from UKB. To our knowledge, no previous MR studies have investigated the interaction between BMI and 25(OH)D.

Previous MR studies investigating each factor separately have demonstrated a causal relationship between higher BMI⁴⁴ and lower 25(OH)D^{14,15} and increased risk for psoriasis. These findings imply that strategies to reduce overweight and vitamin D deficiency in the population may influence the incidence of psoriasis. Complementing these previous findings, our results suggest that targeting both risk factors may be beneficial, but benefit cannot be expected to exceed the additive effect of the two. Although it is difficult to approximate the effect of interventions from MR estimates ⁴⁵⁻⁴⁷, they are valuable for testing causal associations and supporting effect direction of long-term interventions⁴⁶. Public health recommendations for nutrition, physical activity and vitamin D supplementation are relevant examples of such life-long "interventions", which would be extremely difficult to evaluate in trials (which might need follow-up for several decades). A North-American RCT showed a small preventive effect of vitamin D supplements for 5 years on autoimmune disease in general⁴⁸. It was, however, underpowered to provide evidence for prevention of psoriasis specifically, as there were only 38 confirmed psoriasis cases among the ~25 000 participants⁴⁸. Longitudinal studies suggest that weight loss following bariatric surgery can prevent psoriasis in overweight subjects⁴⁹. To our knowledge, no study has evaluated whether other weight reduction strategies have similar preventive effect.

Our findings do not support the effect modification between BMI and 25(OH)D suggested in previous observational studies^{14,17}. However, direct comparison must be done cautiously, as inconsistencies may be explained by methodological differences; MR studies estimate the effect of small differences in life-long exposures, which may be incomparable to the impact of larger exposure differences evaluated over limited time-periods in traditional designs. Traditional observational designs can be affected by bias due to confounding, reverse causation, and measurement error, and violated or weak assumptions may bias MR estimates (discussed further below). That said, we found no

substantial differences between the RERI estimates from MR and traditional analyses in our study, supporting the robustness of our findings. We do, however, recognize that potential interaction effects may be short-term, or manifested only at thresholds or extremes, such as very low 25(OH)D levels or in higher BMI categories. Moreover, interactions may only be relevant for disease activity in established psoriasis, as suggested by our recent study⁵⁰, and not for incident psoriasis.

We have previously argued that overweight and vitamin D deficiency may act synergistically in driving inflammation in psoriasis, considering the link between obesity-associated low-grade inflammation and psoriasis, and the possible role of vitamin D deficiency in the pro-inflammatory state in obesity^{7,50-52}. However, this hypothesis is not supported by the present findings.

Strengths and limitations

The validity of MR effect estimates depend on three core assumptions; (1) *Relevance*; the instrument is robustly associated with the risk factor (exposure), (2) *Independence*; there is no association between the instrument and confounding factors, and (3) *Exclusion restriction*; the instrument is only associated with the outcome through the exposure¹⁹. We confirmed robust associations between the PRSs for both 25(OH)D and BMI in UKB, and BMI in HUNT. Limited measurements prevented us from testing the association with 25(OH)D in HUNT. In a previous study, a PRS based on three SNPs explained 3.7% of the variations of the 25(OH)D levels in a HUNT-subsample (n~6300)⁵³. Evaluating associations between PRSs and known confounders of the observational association are often used to partly assess the second assumption¹⁹. In our study, the BMI-PRS was weakly associated with 25(OH)D, age and sex, and the vitD-PRS weakly associated with BMI in UKB. However, the coefficients were small relative to the main effect on BMI. We can, however, not exclude associations with unknown or unmeasured confounders. Further, we recognize that the association between BMI-PRS and 25(OH)D, as well as the vitD-PRS and BMI, may have unknown effects on the interaction analysis.

When pleiotropy is present, the third assumption is violated¹⁹. Both instruments in our primary analyses have previously been used in one-sample MR with psoriasis as outcome and found to be robust to pleiotropy^{11,37}. Instruments compiling variants in genes with well-known functional link to the exposure reduces risk of pleiotropy. Ideally, we would have included a such focused PRS for BMI as well. However, this was not attempted as most BMI associated variants have unknown functions^{54,55}.

Factorial MR has low power to detect true interaction, even in large samples^{20,21}. The difference in measured BMI (~1.6 kg/m²) and 25(OH)D (~7 nmol/L) between the groups in the 2x2 factorial MR analysis may be too small to detect interaction effects in our study. Comparing groups with genetically predicted larger differences than what is possible using common variants could provide more robust answers. Moreover, in simulation studies, an extension of two-stage least squares approach has been shown to be more efficient for analysing interactions²¹. However, such methods are not yet developed for binary outcomes²¹.

As discussed above, our findings reflect assumingly stable contribution of genetic risk over the lifecourse. This assumption may not hold, as the genetic contribution to BMI or 25(OH)D may differ with the state of the individual (e.g. with concurrent disease), at different time-points during development, or according to environmental exposures (like UV-availability). It is also plausible that the effect of overweight/vitamin D deficiency on psoriasis risk varies through life. Our data did not enable us to incorporate such potential time-varying effects. Life-course studies measuring BMI and 25(OH)D at several time-points may increase our understanding. Research on multiple sclerosis

indicates crucial time-points for the effect of vitamin D on disease risk during childhood or adolescence⁵⁶. To our knowledge, no such study on psoriasis risk has been performed.

Cohort studies tend to recruit the healthiest in the population^{57,58}, and are thereby at risk for selection bias. However, we find it reasonable to assume that the potential effect of participation on BMI, 25(OH)D and genetic variants are independent of outcome status in our study. Any substantial impact on relative differences is therefore unlikely⁵⁹. The consistency of our finding in both cohorts is also reassuring. By using a case definition combining self-report and different sources of diagnosis data, we aimed to include as many psoriasis cases as possible. This case definition has not been validated. Thus, the extent of outcome misclassification is unknown. It is, however, assumable that any expected outcome misclassification is non-differential (i.e. independent of both BMI, 25[OH]D and genetic variants). This may have biased the estimated ORs towards the null⁴¹.

The less clear trend between factorial groups in the 2x2 analysis in HUNT may be attributed to higher random error due to the smaller sample size. Additionally, the high degree of relatedness in the HUNT sample may result in over-precision and family-level bias in our estimate. However, we expect this to be minimal. Some variation between UKB and HUNT may also be due to differences in case definitions, as 55 % of the UKB sample lacked primary care data, and, that self-report in UKB only captures doctor diagnosed psoriasis. The study includes only white subjects of European ancestry and therefore may not be generalizable to other populations.

One strength of our study is that the use of genetic variants as proxies reduces the potential for confounding compared with traditional observational studies. Second, we utilize large-scale population-based cohorts compiling thousands of cases and controls, and thereby any large interaction effect is likely to be detected. We have shown consistent RERI estimates across two independent cohorts and between PRS-combinations. Our RERI estimates shows similar results in both 2x2 and continuous MR approaches, as well as in the observational analysis.

Conclusions

The results from this factorial MR study suggest that there is no relative excess risk for psoriasis due to interaction between BMI and 25(OH)D. That is, the combined effect did not exceed the additive effect of the two factors. Interventions to reduce overweight and vitamin D deficiency in the population, may both influence psoriasis incidence, but the benefit of combined intervention cannot be expected to exceed the additive effect of the two. Considering the small differences in actual BMI and 25(OH)D between the factorial groups, small interaction effects or other threshold effects may have been undetected.

Data Availability Statement

Data may be obtained from a third party and are not publicly available. The UK Biobank resource is available to bona fide researchers for health-related research in the public interest (<u>https://www.ukbiobank.ac.uk/enable-your-research</u>). Access to data from the HUNT Study can be given to researchers with a PhD associated with Norwegian research institutes upon application to HUNT's Data Access Committee, given approval by a Regional Committee for Medical and Health Research Ethics. Researchers outside of Norway are welcome to apply for the use of HUNT data in cooperation with a Norwegian Principal Investigator (<u>https://www.ntnu.edu/hunt/data</u>).

Conflict of Interest Statement

<u>Conflict of interest declaration</u>: Kjersti Danielsen reports to have served as a consultant, lecturer or participated in sponsored events/meetings by Novartis, Abbvie, LEO Pharma, UCB Pharma, Almirall, Meda Pharma, Bristol Myers Squibb, Galderma and Celgene. Other authors: None declared.

<u>Funding sources that supported the work:</u> Marita Jenssen, Kjersti Danielsen and Anne-Sofie Furberg have received research grants from Northern Norway Regional Health Authority (grant number HNF1361-17 (MJ) and SFP1167-14 (KD, ASF), the Odd Berg Medical Research Foundation (MJ, KD) and the Norwegian Society of Dermatology and Venereology (MJ). Mari Løset and Ben Brumpton are supported by grants from the Liaison Committee for Education, Research and Innovation in Central Norway and the Joint Research Committee between St Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU. Yi-Qian Sun was supported by a Researcher grant from the Liaison Committee for Education in Central Norway (project ID 2018/42794). The other authors state no funding supporting the work reported in the manuscript.

The funders were not involved in the design and conduct of the study; nor in the collection, management, analysis, and interpretation of the data; nor in the preparation, review, or approval of the manuscript; nor in the decision to submit the manuscript for publication.

Acknowledgements

We want to thank the participants and staff of the UK Biobank and the Trøndelag Health Study.

The Trøndelag Health Study (HUNT) is a collaboration between HUNT Research Center (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National Institutes of Health; University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. Analyses were performed in digital labs at HUNT Cloud, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.

CredIT statement

Conceptualization: MJ, ML, BOÅ, KD, BMB; Methodology: NA, BMB; Formal analysis: MJ, NA, BMB; Data Curation: LT, BMB; Writing - Original Draft: MJ; Writing - Review & Editing: NA, ML, BOÅ, LT, OJGB, XMM, YQS, ASF, RJ, TW, KD, BMB; Visualization: MJ, NA, BMB; Supervision: KD, BMB; Funding acquisition: KD, BMB

Supplementary material

Online supplementary material.

Figure Legends

Figure 1: Factorial Mendelian randomisation using a 2x2 design.

Adapted from *Rees JMB, Foley CN, Burgess S. Factorial Mendelian randomization: using genetic variants to assess interactions. International Journal of Epidemiology 2019; 49: 1147-58117²⁰. BMI=body mass index. PRS=polygenic risk score. 25(OH)D=25-hydroxyvitamin D. BMI-PRS = the PRS for BMI. VitD-PRS = the PRS for 25(OH)D.*

Figure 2. Odds ratio estimates for psoriasis from factorial Mendelian randomisation (MR) analyses in UK Biobank and HUNT.

(A) Unscaled associations. (B) Associations in UKB scaled to represent a 5 kg/m2 increase in body mass index (BMI) and 10 nmol/L decrease in 25-hydroxyvitamin D (25[OH]D). Upper panel (A and B): Results from 2x2 factorial MR. Participants are separated in four groups based on median PRS for BMI and 25(OH)D[#]. Relative excess risk due to interaction (RERI, 95% CI) was estimated to -0.01(-0.06, 0.09) in UKB and -0.04(-0.14, 0.06) in HUNT. Interaction exists if RERI \neq 0. Lower panel (A and B): Results from continuous factorial MR including the two PRSs on a continuous scale as well as the cross-product between PRSs. RERI (95% CI) was estimated to 0.00(-0.02, 0.02) in UKB and 0.00(-0.03, 0.02) in HUNT.

Footnote: [#]PRSs for body mass index and 25-hydroxyvitamin D. In 2x2 analysis PRSs were dichotomized at the median value, and combined to four groups. Odds ratio estimates derived from logistic regression models adjusted for age, sex, genetic batch and principal components 1 to 20. † Continuous factorial MR included the PRS for BMI, PRS for 25(OH)D (both standardised to have a mean of 0 and standard deviation of 1) and their cross-product. ‡ OR for the additive term of the continuous variables were calculated by exponentiating the sum of estimated beta-values for PRS for BMI (b1), PRS for 25(OH)D (b2) and their cross-product (b3) (i.e. OR = exp[b1+b2+b3]).

HUNT = the Trøndelag Health Study. N=total number of participants. PRS=polygenic risk score. Cl=confidence interval. SD=standard deviation.

Tables

		TABLE 1			
Characteristics of the participants; UK Biobank (n=398 404*) and HUNT (n= 86 648).					
	UK Biobank		HUNT		
	No psoriasis	Psoriasis ¹	No psoriasis	Psoriasis ¹	
Number of participants	386 197/ 96.9	12 207/ 3.1	78 854 / 91.0	7 794 / 9.0	
Age (years)	56.9 (7.9)	57.2 (7.8)	46.2 (17.1)	44.7 (13.8)	
Sex					
Female	208 122 / 53.9	6 056 / 49.6	41 674 / 52.8	4 275 / 54.8	
Male	178 075 / 46.1	6 151 / 50.4	37 180 / 47.2	3 519 / 45.2	
25(OH)D (nmol/L) ²	54.8 (19.7)	53.3 (19.7)	NA	NA	
BMI (kg/m²)	27.4 (4.7)	28.3 (5.1)	26.4 (4.3)	27.0 (4.6)	

Continuous variables given as mean (SD) and categorical as number / proportions.

HUNT = The Trøndelag Health Study. 25(OH)D = serum 25-hydroxyvitamin D. BMI = body mass index. NA=not applicable. ¹ Psoriasis = Medical records and/or self-report

² Season-adjusted (Autumn mean)

*Dataset restricted (omitted participants missing genetic data + unrelated).

2 3 **Factorial Group** 0 1 BMI-PRS¹ < BMI-PRS¹ < $BMI-PRS^{1} >$ $BMI-PRS^1 >$ median median median median VitD-prs² < VitD-prs² > VitD-prs² > VitD-prs² < median median median median UKB Number of participants 99 6 1 6 99 615 99 586 99 587 Psoriasis 2895/2.9 2 983 / 3.0 3 101 / 3.1 3 228 / 3.2 57.0 (7.9) 56.9 (7.9) 56.9 (7.9) 56.9 (7.9) Age Sex 53 757 / 54.0 Female 53 650 / 53.9 53 266 / 53.5 53 505 / 53.7 Male 45 937 / 46.1 46 859 / 46.0 46 349 / 46.5 46 081 / 46.3 BMI^³ 26.6 (4.5) 26.9 (4.5) 28.3 (5.0) 28.2 (5.0) 25(OH)D4 58.5 (20.9) 51.8 (17.8) 57.6 (20.9) 51.1 (17.8) HUNT Number of participants 21 666 21 658 21 658 21 666 Psoriasis 1889 / 8.7 1875 / 8.7 2053 / 9.5 1977 / 9.1 46.2 (17.0) 46.2 (17.0) 46.0 (16.8) 45.9 (16.8) Age Sex Female 11279 / 52.1 11583 / 53.5 11586 / 53.5 11501 / 53.1 Male 10387 / 47.9 10075 / 46.5 10072 / 46.5 10165 / 46.9 BMI⁵ 25.8 (4.0) 25.8 (4.1) 27.1(4.5)27.1 (4.6)

TABLE 2

Basic characteristics of the participants across the 2x2 factorial genetic risk groups. The UK Biobank (n=398 404) and HUNT (n=86 648).

¹ BMI-PRS=polygenic risk score for BMI, 940 SNPs in UKB/941 SNPs in HUNT

² VitD-prs=polygenic risk score for 25(OH)D, 21 SNPs in UKB/19 SNPs in HUNT

³ Missing value in 1262

⁴ Missing value in 35 389

⁵ Missing value in 638

UKB=UK Biobank. HUNT=The Trøndelag Health Study.

Psoriasis = Medical records and/or self-reported.

 $BMI = body mass index (kg/m^2)$. 25(OH)D = serum 25-hydroxyvitamin D (nmol/L), adjusted for season. SNP=single nucleotide polymorphism.

References

- 1 Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. *JAMA* 2020; **323**: 1945-60.
- 2 Parisi R, Iskandar IYK, Kontopantelis E *et al.* National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *BMJ* 2020; **369**: m1590.
- 3 Solvin Å, Bjarkø VV, Thomas LF *et al.* Body Composition, Cardiometabolic Risk Factors and Comorbidities in Psoriasis and the Effect of HLA-C*06:02 Status: The HUNT Study, Norway. *Acta Derm Venereol* 2023; **103**: adv5209.
- 4 Danielsen K, Olsen A, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. *British Journal of Dermatology* 2013; **168**: 1303-10.
- 5 Solberg SM. Psoriasis in Norway: A Prescription-based Registry Study of Incidence and Prevalence. *Acta dermato-venereologica* 2023; **103**: adv4591.
- 6 Iskandar IYK, Parisi R, Griffiths CEM *et al.* Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*. *British Journal of Dermatology* 2021; **184**: 243-58.
- 7 Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations. *Current Obesity Reports* 2020; **9**: 165-78.
- 8 Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. *Nutr Diabetes* 2012; **2**: e54.
- 9 Snekvik I, Smith CH, Nilsen TIL *et al.* Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. *The Journal of investigative dermatology* 2017; **137**: 2484-90.
- 10 Ogawa K, Stuart PE, Tsoi LC *et al.* A Transethnic Mendelian Randomization Study Identifies Causality of Obesity on Risk of Psoriasis. *J Invest Dermatol* 2019; **139**: 1397-400.
- 11 Budu-Aggrey A, Brumpton B, Tyrrell J *et al.* Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. *PLoS medicine* 2019; **16**: e1002739.
- 12 Umar M, Sastry KS, Al Ali F *et al.* Vitamin D and the pathophysiology of inflammatory skin diseases. *Skin pharmacology and physiology* 2018; **31**: 74-86.
- 13 Hambly R, Kirby B. The relevance of serum vitamin D in psoriasis: a review. *Archives* of Dermatological Research 2017; **309**: 499-517.
- 14 Zhang Y, Jing D, Zhou G *et al*. Evidence of a causal relationship between vitamin D status and risk of psoriasis from the UK Biobank study. *Frontiers in nutrition* 2022: 604.
- 15 Zhao SS, Mason A, Gjekmarkaj E *et al.* Associations between vitamin D and autoimmune diseases: Mendelian randomization analysis. *Semin Arthritis Rheum* 2023; **62**: 152238.
- 16 Drodge DR, Budu-Aggrey A, Paternoster L. Causal Analysis Shows Evidence of Atopic Dermatitis Leading to an Increase in Vitamin D Levels. *Journal of Investigative Dermatology* 2021; **141**: 1339-41.
- 17 Kuang Y, Xiao Y, Fang Z *et al.* Association of serum vitamin D with psoriasis and effect modification by central obesity. *Frontiers in Medicine* 2020; **7**: 236.

- 18 Jenssen M, Furberg A-S, Jorde R et al. Effect of Vitamin D Supplementation on Psoriasis Severity in Patients With Lower-Range Serum 25-Hydroxyvitamin D Levels: A Randomized Clinical Trial. JAMA Dermatology 2023.
- 19 Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Human Molecular Genetics* 2014; **23**: R89-R98.
- 20 Rees JMB, Foley CN, Burgess S. Factorial Mendelian randomization: using genetic variants to assess interactions. *International Journal of Epidemiology* 2019; **49**: 1147-58.
- 21 North T-L, Davies NM, Harrison S *et al.* Using Genetic Instruments to Estimate Interactions in Mendelian Randomization Studies. *Epidemiology* 2019; **30**: e33-e5.
- 22 Lash V, Haneuse, Rothman. *Modern Epidemiology*, 4 edn.: Wolters Kluwer. 2021.
- Sudlow C, Gallacher J, Allen N *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Medicine* 2015; **12**: e1001779.
- 24 Rory C. UK Biobank: Protocol for a large-scale prospective epidemiological resource. In. United Kingdom: UK Biobank. 2007.
- 25 Åsvold BO, Langhammer A, Rehn TA *et al.* Cohort profile update: the HUNT study, Norway. *International journal of epidemiology* 2023; **52**: e80-e91.
- 26 Krokstad S, Langhammer A, Hveem K *et al.* Cohort Profile: the HUNT Study, Norway. *Int J Epidemiol* 2013; **42**: 968-77.
- 27 Brumpton BM, Graham S, Surakka I *et al.* The HUNT Study: a population-based cohort for genetic research. *Cell Genomics* 2022; **2**: 100193.
- 28 Modalsli EH, Snekvik I, Åsvold BO *et al.* Validity of Self-Reported Psoriasis in a General Population: The HUNT Study, Norway. *J Invest Dermatol* 2016; **136**: 323-5.
- 29 Bycroft C, Freeman C, Petkova D *et al.* Genome-wide genetic data on~ 500,000 UK Biobank participants. *BioRxiv* 2017: 166298.
- 30 Mitchell R, Hemani, G, Dudding, T, Paternoster, L. UK Biobank Genetic Data: MRC-IEU Quality Control, Version 1 (2017). https://doi.org/10.5523/bris.1ovaau5sxunp2cv8rcy88688v.
- 31 Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization. *International Journal of Epidemiology* 2013; **42**: 1134-44.
- 32 Yengo L, Sidorenko J, Kemper KE *et al.* Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* 2018; **27**: 3641-9.
- 33 Locke AE, Kahali B, Berndt SI *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* 2015; **518**: 197-206.
- 34 Zhou A, Selvanayagam JB, Hyppönen E. Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk. *European Heart Journal* 2022; **43**: 1731-9.
- 35 Zhou A, Hyppönen E. Vitamin D deficiency and C-reactive protein: a bidirectional Mendelian randomization study. *Int J Epidemiol* 2023; **52**: 260-71.
- Sofianopoulou E, Kaptoge SK, Afzal S *et al.* Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. *The Lancet Diabetes & Endocrinology* 2021;
 9: 837-46.
- 37 Sofianopoulou E, Kaptoge SK, Afzal S *et al.* Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational

and Mendelian randomisation analyses. *The Lancet Diabetes & Endocrinology* 2021; **9**: 837-46.

- Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet (London, England)* 2004;
 363: 157-63.
- Lin L-Y, Smeeth L, Langan S, Warren-Gash C. Distribution of vitamin D status in the UK: a cross-sectional analysis of UK Biobank. *BMJ Open* 2021; **11**: e038503.
- 40 Sun Y-Q, Langhammer A, Skorpen F *et al.* Serum 25-hydroxyvitamin D level, chronic diseases and all-cause mortality in a population-based prospective cohort: the HUNT Study, Norway. *BMJ open* 2017; **7**: e017256.
- 41 Rothman KJ, Lash TL, VanderWeele TJ, Haneuse S. *Modern epidemiology*, Fourth edition edn. Philadelphia: Wolters Kluwer / Lippincott Williams & Wilkins. 2021.
- 42 Knol MJ, van der Tweel I, Grobbee DE *et al.* Estimating interaction on an additive scale between continuous determinants in a logistic regression model. *International Journal of Epidemiology* 2007; **36**: 1111-8.
- 43 Chang CC, Chow CC, Tellier LC *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience* 2015; **4**.
- 44 Budu-Aggrey A, Brumpton B, Tyrrell J *et al.* Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. *PLOS Medicine* 2019; **16**: e1002739.
- 45 Swanson SA, Tiemeier H, Ikram MA, Hernán MA. Nature as a Trialist?: Deconstructing the Analogy Between Mendelian Randomization and Randomized Trials. *Epidemiology* 2017; **28**: 653-9.
- 46 Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to assess potential benefit of clinical intervention. *Bmj* 2012; **345**.
- 47 Ference BA. How to use Mendelian randomization to anticipate the results of randomized trials. *European Heart Journal* 2017; **39**: 360-2.
- 48 Hahn J, Cook NR, Alexander EK *et al.* Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. *Bmj* 2022; **376**.
- 49 Mahil SK, McSweeney SM, Kloczko E *et al.* Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic. *British Journal of Dermatology* 2019; **181**: 946-53.
- 50 Jenssen M, Furberg A-S, Jorde R *et al.* The association between serum 25hydroxyvitamin D levels and psoriasis in a large population-based cohort, a crosssectional analysis of The Tromsø Study 2015-16. *British Journal of Dermatology* 2023.
- 51 Jensen P, Skov L. Psoriasis and Obesity. *Dermatology* 2016; **232**: 633-9.
- 52 Todosenko N, Vulf M, Yurova K *et al.* Causal Links between Hypovitaminosis D and Dysregulation of the T Cell Connection of Immunity Associated with Obesity and Concomitant Pathologies. *Biomedicines* 2021; **9**: 1750.
- 53 Mai X-M, Videm V, Sheehan NA *et al.* Potential causal associations of serum 25hydroxyvitamin D with lipids: a Mendelian randomization approach of the HUNT study. *Eur J Epidemiol* 2019; **34**: 57-66.
- 54 Loos RJ, Yeo GS. The genetics of obesity: from discovery to biology. *Nature Reviews Genetics* 2022; **23**: 120-33.

- 55 Speakman J, Loos R, O'Rahilly S *et al.* GWAS for BMI: a treasure trove of fundamental insights into the genetic basis of obesity. *International journal of obesity* 2018; **42**: 1524-31.
- 56 Sundström P, Salzer J. Vitamin D and multiple sclerosis—from epidemiology to prevention. *Acta Neurologica Scandinavica* 2015; **132**: 56-61.
- 57 Jacobsen BK, Eggen AE, Mathiesen EB *et al.* Cohort profile: The Tromsø Study. *International Journal of Epidemiology* 2011; **41**: 961-7.
- 58 Langhammer A, Krokstad S, Romundstad P *et al.* The HUNT study: participation is associated with survival and depends on socioeconomic status, diseases and symptoms. *BMC Medical Research Methodology* 2012; **12**: 143.
- 59 Szklo M, Nieto FJ. *Epidemiology: beyond the basics*, 4 edn.: Jones & Bartlett Publishers. 2019.

Factorial Mendelian randomisation		BMI-PRS		
		Below median	Above median	
VitD-PRS	Above median	BMI lower 25(OH)D higher	BMI higher 25(OH)D higher	
	Below median	BMI lower 25(OH)D lower	BMI higher 25(OH)D lower	

PRS BMI - PRS 25(OH)D [#]	N (Psoriosis ossos)	Change in	
	(FSOFIASIS Cases)		
		kg/m ²	
Α			
2x2 analysis			
BMI lower, 25(OH)D higher	99 587 (2 895)	Reference	
BMI lower, 25(OH)D lower	99 616 (2 983)	-0.07 (-0.11, -0.0	
BMI higher, 25(OH)D higher	99 615 (3 101)	1.64 (1.59, 1.68)	
BMI higher, 25(OH)D lower	99 586 (3 228)	1.61 (1.57, 1.65)	
Continuous analysis			
meRxix preprint Si Lh par/Loi. org/10 11(1) 2014 07.012430 Cet; his arson costed July 3, 2024. The organized with the second sec	copyright have the preprint in perpetuity. (12 207)	1.05 (1.03, 1.06)	
PRS 25(OH)D (1 SD decrease)	398 404 (12 207)	-0.02 (-0.04, -0.0	
Cross - product term [†]			
Additive term [‡]			
B			
2x2 analysis			
BMI lower, 25(OH)D higher	99 587 (2 895)	Reference	
BMI lower, 25(OH)D lower	99 616 (2 983)	0	
BMI higher, 25(OH)D higher	99 615 (3 101)	5	
BMI higher, 25(OH)D lower	99 586 (3 228)	5	
Continuous analysis			

PRS BMI	398 404 (12 207)	5
PRS 25(OH)D	398 404 (12 207)	(



			HUN
ratio	Ν	Change in	Change in
CI)	(Psoriasis cases)	BMI	25(OH)D
		kg/m ²	nmol/L
	21 (((1.000))		
erence	21 666 (1 889)	Reference	—
.99, 1.09)	21 658 (1 875)	-0.04 (-0.12, 0.04)	_
.02, 1.13)	21 658 (2 053)	1.23 (1.15, 1.31)	_
.07, 1.18)	21 666 (1 977)	1.28 (1.20, 1.37)	_
.02, 1.06)	86 648 (7 794)	0.81 (0.78, 0.84)	_
.00, 1.04)	86 648 (7 794)	-0.01 (-0.04, 0.02)	_
.98, 1.01)			

1.06 (0.98, 1.15)

1.20 (1.11, 1.31)

